TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00030355
Drug: homoharringtonine
Normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06187311
Drug: Rivaroxaban 20 MG
Normalized name: rivaroxaban 20 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
Study: NCT06187311
Drug: Rivaroxaban 15 MG
Normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
Study: NCT02645734
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg of bevacizumab is injected
Study: NCT02645734
Drug: ziv-aflibercept 1.25 mg
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg of ziv-aflibercept is injected
Study: NCT02645734
Drug: ziv-aflibercept 2.5mg
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5 mg of ziv-aflibercept is injected
Study: NCT05035095
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a daily dose of oral semaglutide.
Study: NCT05660213
Drug: Atezolizumab + Bevacizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study: NCT05660213
Drug: Camrelizumab+Apatinib
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study: NCT05660213
Drug: Sintilimab+Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study: NCT05950971
Drug: Amiodarone, diltiazem or esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.
Study: NCT06205342
Drug: Mesenchymal Stem Cells
Normalized name: Placental Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow derived MSCs
Study: NCT05312190
Drug: ZhenQi BuXue KouFuYe
Normalized name: Buxus Chinensis Oil
DrugBank: Jojoba oil (DB14252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
Study: NCT05100446
Drug: Amoxicillin - high dose dual therapy
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.
Study: NCT05100446
Drug: Pylera
Normalized name: Pylera
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eradication with Pylera, for 10 days.
Study: NCT05100446
Drug: Esomeprazole 40mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40mg, twice a day.
Study: NCT06180707
Drug: pregabalin gel
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
Study: NCT05312190
Drug: Progesterone Capsules
Normalized name: Progesterone Capsules
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
Study: NCT06180707
Drug: gel with 5% potassium nitrate and 2% sodium fluoride
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
Study: NCT06507488
Drug: Daphnetin Capsule
Normalized name: Daphnetin
DrugBank: Daphnetin (DB18965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .
Study: NCT06439303
Drug: Cytisine 1,5 mg
DrugBank: Cytisine (DB09028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
Study: NCT05261009
Drug: Peri-capsular Nerve Group (PENG)
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PENG block for postoperative pain management
Study: NCT05504577
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
Study: NCT05445882
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.
Study: NCT05445882
Drug: N-803
Normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.
Study: NCT05544227
Drug: SV-102
Normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
Study: NCT06532253
Drug: NVDX3
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)
Study: NCT05507645
Drug: Recombinant Human Prourokinase for Injection (rhPro-UK)
Normalized name: hyaluronidase, human recombinant Injection
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
Study: NCT04890106
Drug: Test - Bimatoprost 0.01% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
Study: NCT05453448
Drug: tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antiviral therapy
Study: NCT05453448
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: entecavir
Study: NCT04796025
Drug: Sintilimab; Bevacizumab Biosimilar
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
Study: NCT04839536
Drug: Sevoflurane inhalant product
Normalized name: sevoflurane Inhalant Product
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
Study: NCT05794828
Drug: Bupivacaine Injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
Study: NCT05995899
Drug: Tenapanor
Normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IBS-C patients will ingest one capsule of tenapanor (50 mg per dose), twice daily, before breakfast and dinner for a total of 8 weeks
Study: NCT05845307
Drug: TTI-101
Normalized name: TTI-101
DrugBank: TTI-101 (DB17578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT02571608
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
Study: NCT05446623
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.
Study: NCT05316493
Drug: Megestrol Acetate 160 MG Oral Tablet
Normalized name: megestrol acetate 160 MG Oral Tablet
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enrolled participants will take Megestrol Acetate 160mg daily
Study: NCT05316493
Drug: Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: enrolled patients will be treated with LNG-IUS.
Study: NCT00438789
Drug: eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600mg IV every week and 900mg IV every 2 weeks
Study: NCT06025409
Drug: Leuprolide Acetate 11.25 MG/ML
Normalized name: leuprolide acetate 11.25 MG/ML
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05586841
Drug: Dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib: 100 mg/d or 125 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
Study: NCT05586841
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide: 25 mg/BIW or 20 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
Study: NCT05195645
Drug: Abatacept 250 MG
Normalized name: abatacept 250 MG
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
Study: NCT06351891
Drug: 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Levofloxacin 500mg qd,14 days.
Study: NCT05340790
Drug: Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Normalized name: afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
Study: NCT05340790
Drug: Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Normalized name: afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
Study: NCT05842681
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone 500 mg single intra-venous daily dose for three days
Study: NCT06186986
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
Study: NCT06648772
Drug: Roflumilast Cream 0.3%
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast Cream 0.3%
Study: NCT03098225
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
Study: NCT04599465
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT04647084
Drug: Lidocaine 2% Injectable Solution
Normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An elastic band will be placed around the subject's arm, and the elastic band will be removed once the IV is inserted. After the elastic band is placed on the subject's arm, the arm will be cleaned, and then a small skin wheel will be created with the lidocaine that will be injected very close to where the IV will be placed. The IV will be placed within about a minute from the time when the lidocaine was injected.
Study: NCT00073203
Drug: Placebo and Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05767827
Drug: ropivacaine, lidocaine with adrenaline
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
Study: NCT05767827
Drug: Dexmedetomidine, ropivacaine, lidocaine with adrenaline
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
Study: NCT00445250
Drug: Calcipotriol
Normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06464263
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: to investigate the postoperative analgesic-sedative effect of dexmedetomidine versus fentanyl-midazolam to achieve fast-track extubation after adult valvular cardiac surgeries.
Study: NCT05464368
Drug: 18F-MK6240
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy.
Study: NCT05464368
Drug: 18F-GTP1
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location.
Study: NCT05632848
Drug: Chidamide combined with Zimberelimab
Normalized name: miconazole
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
Study: NCT06351566
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (cholecalciferol), 1600 IU per day.
Study: NCT05064397
Drug: Eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptinezumab will be administered per schedule specified in the arm description.
Study: NCT05987956
Drug: Alectinib - Usual
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Usual Alectinib Chemotherapy (NDC...01)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily
Study: NCT05987956
Drug: Alectinib - Study
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study Alectinib Chemotherapy (NDC...86)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily
Study: NCT06409845
Drug: Eptinezumab 100 or 300 mg ev
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention
Study: NCT04799353
Drug: Budigalimab
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC)
Study: NCT04799353
Drug: Budigalimab
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT00043212
Drug: Dendritic cell immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05112081
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The group will receive a solution of 100 units BTX with 10 ml sterile saline close to the superficial inguinal ring.
Study: NCT06185608
Drug: 0.25% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 15 ml of 0.25% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
Study: NCT06185608
Drug: 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 15 ml of 0.5% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
Study: NCT06185608
Drug: 1% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 15 ml of 1% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
Study: NCT04985669
Drug: Prucalopride 2mg
Normalized name: PRUCALOPRIDE 2MG TAB
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
Study: NCT05348239
Drug: Sodium Copper Chlorophyllin
Normalized name: sodium copper chlorophyllin
DrugBank: Sodium copper chlorophyllin (DB16522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.